Table 3.
Comparison of the diagnostic criteria under specific conditions.
| Overall (n = 113) | Antibody | p | Cancer | p | |||
|---|---|---|---|---|---|---|---|
| Presence (n = 90) | Absence (n = 23) | Presence (n = 81) | Absence (n = 32) | ||||
| Age at onset, years, median (IQR) | 60.0 (53.0–65.0) | 60.0 (54.0–65.8) | 56.0 (50.5–61.5) | 0.080 | 59.0 (53.0–65.0) | 60.0 (52.25–65.0) | 0.781 |
| Male | 69 (61.1) | 51 (56.7) | 18 (78.3) | 0.098 | 50 (61.7) | 19 (59.4) | 0.986 |
| Clinical phenotype | |||||||
| 2004 criteria | |||||||
| Classical | 80 (70.8) | 61 (67.8) | 19 (82.6) | 0.255 | 58 (71.6) | 22 (68.8) | 0.943 |
| Non-classical | 33 (29.2) | 29 (32.2) | 4 (17.4) | 23 (28.4) | 10 (31.2) | ||
| 2021 criteria | |||||||
| High-risk | 68 (60.2) | 50 (55.6) | 18 (78.3) | 0.081 | 50 (61.7) | 18 (56.2) | 0.747 |
| Intermediate-risk | 45 (39.8) | 40 (44.4) | 5 (21.7) | 31 (38.3) | 14 (43.8) | ||
| Antibody | |||||||
| 2004 criteria | |||||||
| Well-characterized | 67 (59.3) | 67 (74.4) | 0 (0.0) | <0.001 | 46 (56.8) | 21 (65.6) | 0.389 |
| Partially characterized | 0 | 0 | 0 | 0 | 0 | ||
| Others or negative | 46 (40.8) | 23 (25.6) | 23 (100.0) | 35 (43.2) | 11 (34.3) | ||
| 2021 criteria | |||||||
| High-risk | 69 (61.1) | 69 (76.7) | 0 (0.0) | <0.001 | 48 (59.3) | 21 (65.6) | 0.003 |
| Intermediate-risk | 20 (17.7) | 20 (22.2) | 0 (0.0) | 10 (12.3) | 10 (31.2) | ||
| Low-risk/negative | 24 (21.2) | 1 (1.1) | 23 (100.0) | 23 (28.4) | 1 (3.1) | ||
| Cancer | |||||||
| 2004 criteria | |||||||
| Presence | 81 (71.7) | 59 (65.6) | 22 (95.7) | 0.009 | 81 (100.0) | 0 (0.0) | <0.001 |
| Absence | 32 (28.3) | 31 (34.4) | 1 (4.3) | 0 (0.0) | 32 (100.0) | ||
| 2021 criteria | |||||||
| Found, consistent with phenotype and (if present) antibody, or not consistent but antigen expression demonstrated | 60 (53.1) | 43 (47.8) | 17 (73.9) | 0.081 | 60 (74.1) | 0 (0.0) | <0.001 |
| Not found/consistent but follow-up < 2 years | 26 (23.0) | 23 (25.6) | 3 (13.0) | 7 (8.6) | 19 (59.4) | ||
| Not found but follow-up ≥ 2 years | 27 (23.9) | 24 (26.7) | 3 (13.0) | 14 (17.3) | 13 (40.6) | ||
| Diagnostic level | |||||||
| 2004 criteria | |||||||
| Definite | 97 (85.8) | 78 (86.7) | 19 (82.6) | 0.870 | 76 (93.8) | 21 (65.6) | <0.001 |
| Possible | 16 (14.2) | 12 (13.3) | 4 (17.4) | 5 (6.2) | 11 (34.4) | ||
| 2021 criteria | |||||||
| Definite | 42 (37.2) | 42 (46.7) | 0 (0.0) | <0.001 | 42 (51.9) | 0 (0.0) | <0.001 |
| Probable | 49 (43.4) | 32 (35.6) | 17 (73.9) | 27 (33.3) | 22 (68.8) | ||
| Possible | 19 (16.8) | 16 (17.8) | 3 (13.0) | 9 (11.1) | 10 (31.2) | ||
| Non-PNS | 3 (2.7) | 0 (0.0) | 3 (13.0) | 3 (3.7) | 0 (0.0) | ||
| PNS-Care Score, median (IQR) | |||||||
| Clinical level | 3.0 (2.0–3.0) | 3.0 (2.0–3.0) | 3.0 (3.0–3.0) | 0.048 | 3.0 (2.0–3.0) | 3.0 (2.0–3.0) | 0.594 |
| Laboratory level | 3.0 (2.0–3.0) | 3.0 (3.0–3.0) | 0.0 (0.0–0.0) | <0.001 | 3.0 (0.0–3.0) | 3.0 (2.0–3.0) | 0.159 |
| Cancer | 4.0 (1.0–4.0) | 1.0 (0.0–4.0) | 4.0 (2.50–4.0) | 0.033 | 4.0 (1.0–4.0) | 1.0 (0.0–1.0) | <0.001 |
| Total | 7.0 (6.0–9.0) | 7.0 (6.0–9.0) | 7.0 (5.0–7.0) | 0.022 | 8.0 (6.0–10.0) | 6.0 (5.0–6.0) | <0.001 |
Numbers (%) are for all patients unless otherwise stated.
IQR, interquartile range; PNS, paraneoplastic neurologic syndrome.